Onnit’s Chief Fitness Officer Discovered His ‘Non-Negotiables’ in 2020

This article originally appeared in the December 2020 issue of Men’s Health.

Onnit Chief Fitness Officer John Wolf shares some of the most important lessons he's learned while adjusting to the challenges that arose in 2020.

© Kyle Hilton
Onnit Chief Fitness Officer John Wolf shares some of the most important lessons he’s learned while adjusting to the challenges that arose in 2020.

JOHN WOLF’S job is all about thinking in new ways to break away from conventions—but 2020 was still an unprecedented challenge for him.

The man tasked with leading the fitness curriculum at Onnit, the company behind some of the most unconventional, versatile workout gear on the market, had to adjust the ways he approaches both his work and family.

He wound up building stronger connections than ever before.

Now, in his own words, Wolf shares the lessons he’s learned through a period that was challenging and isolating—but which ultimately led to deeper connections and a renewed sense of focus.

background pattern: breaker

© .

I think fitness is taking on a little more of a mental-emotional aspect during this pandemic. It is a thing that people have doubled down on in a variety of different ways, but it looks and feels so much different than it did before.

The availability of the equipment is a big issue these days. It’s forced kind of a Spartan and minimalist mindset, like, ‘How creative do I have to be to get the job done?’

Some of the coaching I’ve gone through for personal improvement is what I lean on in this larger group environment because it’s not like everybody looks the same. Not everybody has the same interests—except for everybody feels that they’re alone, to some degree, that their circumstances are uniquely theirs … Then through breaking down the barriers in the group, and me also being vulnerable to my experiences live and being forthright with them about those things, hoping that we’re facilitating an environment where people realize okay, the circumstances might all be really different, but the subjective experience that we’re all having is very consistent as human beings.

logo: Click here to join for more exclusive health and fitness stories.

© .
Click here to join for more exclusive health and fitness stories.

In this day and age, right now, the sense of feeling seen and feeling heard—to feel validated on some platform in some way—takes on a greater meaning and grander meaning than it ever has before… That’s really the biggest message, you show up here and you are seen and you are heard, and that even just that the act of showing up is enough to participate.

If it’s a nice day, we create a space where we can go for an hour-long walk as a pack. Walking together creates either quiet time, being around each other, being okay being quiet, and/or the perfect storm, the perfect opportunity to be able to converse about things that matter and observe the world around us at a tempo where there’s actually time to see something. You drive down the same street, you don’t see the detail on that flower. You might not even notice that those flowers bloomed between yesterday and today.

If you’re

Read More

United Family Medicine Board Names Chief Executive Officer

ST. PAUL, Minn.–(BUSINESS WIRE)–United Family Medicine (UFM), a federally-qualified health center (FQHC) in St. Paul dedicated to meeting the health care demands of its community while contributing to the vitality of the region, announced today that its board of directors promoted Ann Nyakundi to CEO effective immediately.

Nyakundi joined the organization as interim CEO in October 2019, establishing priorities to re-design UFM’s care model to improve patients’ access to its services, maintain highest level health outcomes, and achieve compliance with the Health Resources Services Administration (HRSA), its federal regulator and primary funder. The resulting transformative changes, including migrating from its Allina-leased provider arrangement to hiring its own full complement of physicians, place UFM on track to attain regulatory compliance, while improving patients’ ability to see their doctors and health care team more quickly than ever before.

“It’s my desire and our collective responsibility to provide the best health care possible to every one of our patients, at the time that they need it, and we’re making numerous changes to meet this commitment,” said Nyakundi. “I’m grateful to UFM’s board of directors for the confidence it’s placed in me as its CEO, and excited to continue our work to place patients at the center of our response to community needs.”

Through the onset and continuing stressors of the Covid-19 pandemic, Nyakundi empowered her teams to improve access to care, such as the advanced practitioners who launched telemedicine as a service. This prompt response resulted in UFM regaining most of the patient visits that were delayed due to the pandemic, while significantly reducing UFM’s operating deficit and reliance on a part-time physician workforce. These cost efficiencies will allow UFM to expand dental and other services.

“Ann’s skill as a health care leader and her ethical and motivational orientation has steered United Family Medicine forward through the extreme challenges that its operating structure posed and the Covid-19 pandemic continues to present,” said Daymond Dean, UFM Executive Committee Board Member. “Our patients’ lives and well-being depend on their ability to receive the services that a community health center provides, and Ann is immeasurably qualified to ensure that UFM delivers those services and high-quality health care to our community.

Nyakundi pursued undergraduate and graduate medical anthropology and health care administration at the University of Michigan and University of Minnesota respectively, and brings to her role expertise in community health, philanthropy, strategic planning and health policy. Having experienced homelessness as a child without access to adequate options for high quality health care, inspired her career and commitment to public health. Most recently she volunteered for the Agency for Healthcare Research and Quality (AHRQ) as a National Expert for the New Models of Primary Care Workforce and Financing Project, provided strategic support to the National Marrow Donor Program and worked within the Primary Care Services Division of the American Cancer Society.

About United Family Medicine

United Family Medicine, a federally qualified health center in St. Paul, Minnesota, provides high quality primary care, dental services and

Read More

Sunday Times – Residents in quarantined CMC flats asked to submit medicine list to police or UDA officer in the premises


Those residing in quarantined urban flats in Colombo Municipal Council area are requested to submit their dispensary/hospital medicine prescription if suffering from long term, chronic health conditions, Director General of Health Services Dr. Asela Gunawardena has requested.

Residents of Muwadora Uyana, Sirimuthu Uyana, Sirisanda Sevana, Randiya Uyana, Methsada Sevana, Minijaya Sevana, Ranmit Sevana, Sathhiru Sevana, N.H.S. Maligawatte in Colombo city who suffer from diabetes, high blood pressure, heart disease, epilepsy, wheezing, high blood cholesterol, kidney disease and cancer are requested to inform the police officer or the person from the Urban Development Authority in charge of their floors about such illnesses and the need to get medicine.

They will be required to submit their name, age, address and name of the dispensary or hospital they usually get medicine from.

Dr. Gunawardena said the monthly medicine pack will be delivered by the officers and requested the residents to avoid leaving their houses.

Source Article

Read More

Editas Medicine Reports Inducement Grants to New Chief Medical Officer

CAMBRIDGE, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the grant of inducement awards to the Company’s newly appointed Executive Vice President and Chief Medical Officer, Lisa Michaels, M.D. In connection with Dr. Michaels’ appointment, the Editas Medicine Board of Directors approved a stock option grant and a restricted stock unit award to Dr. Michaels as inducements material to Dr. Michaels entering into employment with Editas Medicine in accordance with Nasdaq Listing Rule 5635(c)(4).  The stock option provides for the purchase of up to 120,000 shares of Editas Medicine common stock at a price of $30.41 per share, the closing price per share of Editas Medicine common stock as reported by Nasdaq on the date of grant, and vests over four years, with 25 percent of the shares vesting on the first anniversary of Dr. Michaels’ employment start date, and the remainder vesting ratably at the end of each subsequent month thereafter, subject to Dr. Michaels’ continued service relationship with Editas Medicine through the applicable vesting dates. The restricted stock unit award is for 20,000 shares of Editas Medicine common stock and vests as to 25 percent of the shares on each one-year anniversary of Dr. Michaels’ employment start date until the fourth anniversary of Dr. Michaels’ employment start date, subject to Dr. Michaels’ continued service to Editas Medicine through the applicable vesting dates.

About Editas Medicine
As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit

CONTACT: Contacts: Media Cristi Barnett (617) 401-0113 [email protected] Investors Mark Mullikin (617) 401-9083 [email protected]

Source Article

Read More

Editas Medicine Appoints Lisa A. Michaels, M.D., as Chief Medical Officer

CAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it named Lisa A. Michaels, M.D., as the Company’s Executive Vice President and Chief Medical Officer, effective immediately. Dr. Michaels will lead clinical research and drug development for the Company’s pipeline of experimental medicines.

“We are thrilled to have Lisa join our team, bringing her ability to translate concepts from ‘bench to bedside’, with proven results in design and execution of multinational clinical trials,” said Cynthia Collins, President and Chief Executive Officer, Editas Medicine. “Her corporate and academic drug development expertise will be instrumental in advancing our mission to develop and deliver transformative medicines to people living with serious diseases.”

Lisa Michaels, M.D., Executive Vice President and Chief Medical Officer, Editas Medicine, commented, “Editas Medicine is a leader in the development of the next generation of medicines to treat diseases with few approved medicines. I am excited to join the team as we just reacquired the rights to our ocular pipeline and are on the cusp of bringing EDIT-301, our potentially best-in-class medicine for the treatment of sickle cell disease, to the clinic. I look forward to working with the team to advance the development of EDIT-101, EDIT-301, and EDIT-201 in the near term as well as additional medicines in the future to treat serious diseases with unmet medical needs.”

Dr. Michaels has more than 25 years of experience in clinical research and drug development in both industry and academia. Dr. Michaels joins Editas Medicine from Bayer Pharmaceuticals where she spent more than 10 years in drug development, leading teams from early research and drug discovery through regulatory approval, commercial launch, and life cycle management. Most recently, she served as head of Bayer’s Rare Diseases, Cell & Gene Therapy therapeutic area.

Earlier in her career, Dr. Michaels spent more than 15 years at the Robert Wood Johnson Medical School at Rutgers University in academic practice, working in areas including benign and malignant hematology, solid tumors, bone marrow failure syndromes, thrombosis and hemostasis, and immunologic disorders including cytopenias and immune deficiencies.

Dr. Michaels received her M.D. at the University of Virginia, Charlottesville during which she received additional training in translational research in autoimmune disease, immune deficiencies, and disorders of complement, at the National Institute for Allergy and Infectious Disease in Washington, DC, and completed a preceptorship in pediatric cardiovascular care at Mayo Clinic, in Rochester, Minnesota. Dr. Michaels completed her residency and qualification in pediatrics at Duke University and post-graduate fellowship and qualification in hematology and oncology at the Children’s Hospital of Philadelphia.

About Editas Medicine
As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cpf1 (also known as Cas12a) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of

Read More

Mission Therapeutics Appoints Dr Suhail Nurbhai as Chief Medical Officer

Mission Therapeutics (“Mission”), a drug discovery and development company focused on selectively inhibiting deubiquitylating enzymes (DUBs), has appointed Dr Suhail Nurbhai as Chief Medical Officer (CMO) with immediate effect.

This press release features multimedia. View the full release here:

Dr Suhail Nurbhai. High-resolution images available on request. (Photo: Business Wire)

Dr Nurbhai has more than 25 years of experience and a strong track record in the strategic and operational leadership of all phases of clinical research and development at companies across Europe and the US. He joins Mission from VHsquared, where he held the position of CMO since 2014.

Prior to VHsquared, Suhail was Senior Vice President and Head of Development and Medical Affairs for Shionogi in Europe. He joined Shionogi from Takeda where he was Vice President and Head of Clinical and Analytical Science in Europe, with responsibility for all Clinical Science activities in Neurosciences, Cardiovascular/Renal/Metabolic, Oncology, Gastrointestinal/Genitourinary and Respiratory Medicine, as well as Clinical Pharmacology, Medical Writing, Statistics and Data Management.

Suhail’s initial industry experience was at Pfizer, where he spent 12 years, initially in Sandwich, UK and then at Global R&D Headquarters in Connecticut, USA. During his time at Pfizer he held roles of increasing responsibility across multiple therapeutic areas including GI/GU, anti-bacterial, sexual medicine and anti-fungal, prior to completing his time at Pfizer as Head of Neuroscience Clinical R&D at the Groton site in Connecticut.

During his career he has led teams bringing multiple compounds from pre-clinical phase into clinical studies in both Europe and US, and achieved multiple successful NDA and MAA submissions and approvals.

Suhail qualified in Medicine at Dundee University in Scotland and completed his post-graduate medical training at Hope Hospital in the University of Manchester.

Commenting on the appointment, Dr Anker Lundemose, CEO of Mission Therapeutics said: “We are pleased to be welcoming Suhail to further strengthen Mission’s leadership team. His in-depth knowledge and proven track record in clinical research will be invaluable as we work to bring our first-in-class USP30 inhibitor compound into the clinic. Suhail’s appointment is the last of a series of organisational changes, including the promotions of Dr Paul Thompson and Dr Nick Edmunds, to ready the Company for this next phase.”

Dr Suhail Nurbhai added: “It’s great to be joining Mission at such an exciting time for the Company. The ongoing collaboration with AbbVie and recently signed agreement with Pfizer represent solid industry validation of the Company’s approach and ground-breaking technology. I look forward to building on this success progressing its lead assets into the clinic.”

– ENDS –


About Mission Therapeutics

Mission Therapeutics is an early-stage drug development company targeting the ubiquitin pathway for the treatment of kidney disease, neurodegenerative disease, rare mitochondrial diseases and fibrosis. The Company has built a leading platform for the discovery and development of first-in-class, small molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging drug class that is attracting significant commercial interest in the area of protein homeostasis.

Mission has strong

Read More

Providence Names Sylvain Trepanier as Chief Nursing Officer

Providence Names Sylvain Trepanier as Chief Nursing Officer

PR Newswire

RENTON, Wash., Oct. 29, 2020

RENTON, Wash., Oct. 29, 2020 /PRNewswire/ — Providence, one of the largest health systems in the country, today announced that Sylvain “Syl” Trepanier, D.N.P., R.N., will serve as the organization’s new system-wide chief nursing officer (CNO), effective January 1, 2021.

Sylvain “Syl” Trepanier, D.N.P., R.N., will serve as the organization’s new system-wide chief nursing officer (CNO), effective January 1, 2021
Sylvain “Syl” Trepanier, D.N.P., R.N., will serve as the organization’s new system-wide chief nursing officer (CNO), effective January 1, 2021

As the new CNO, Syl will be a critical voice for nursing at the senior executive level, advocating for nurses and advanced practitioners while supporting the practice of nursing across the health system’s seven-state footprint. He will play a meaningful role in setting the system’s clinical strategy and will be at the center of workforce planning. One of Syl’s earliest responsibilities will be continuing to build momentum for Providence’s Nursing Institute and Clinical Academy, programs that provide a sustained talent pipeline of specialty nurses, nurse practitioners and clinicians.

“The CNO serves as a champion for our nurses and the invaluable role they play caring for the people in our communities, as well as ensuring we are attracting and retaining the most skilled and compassionate nurses. I know Syl will do both,” said executive vice president and chief clinical officer, Amy Compton-Phillips, M.D., to whom he will report. “With 30,000 nurses, we have a unique opportunity to show how nurses are at the heart of our mission and helping achieve our vision of health for a better world.”

Syl is currently serving as the chief clinical executive for Providence’s Southern California region. His work reduced clinical variation across the region, making Providence Southern California one of the safest places to receive care. Additionally, Syl helped lead the COVID-19 response. “Our region’s COVID-19 response demonstrates how the sharing of expertise across our system results in top-quality care, innovation and increased collaboration. I am excited to continue this work with my nursing colleagues across the Providence family of organizations,” said Syl.  

Syl will follow Deb Burton, Ph.D., R.N., who will retire at the end of 2020 after serving 12 years as the CNO for Providence. Under Deb’s leadership, Providence’s successful nursing workforce development programs have gained national recognition. The Clinical Academy, a year-long program designed to launch the careers of new graduate nurses into 22 different clinical specialties, resulted in a reduction in first-year nursing turnover from 25% to roughly 9% today. Deb also led efforts to grow distance-based academic nursing and clinical programs through the University of Providence.

Prior to joining Providence Southern California in 2017, Syl served as system vice president and chief nursing officer for Premier Health in Dayton, Ohio. He also held leadership roles at Tenet in Dallas and at hospitals in South Florida. He has a doctorate in nursing from Texas Tech University, a Master of Science in Nursing, and a Bachelor of Science in Nursing from the University of Montreal.

Read More

Second highest ranking officer in US Space Force tests positive for Covid-19

“General David D. Thompson, Vice Chief of Space Operations, tested positive today for COVID-19. He took the test today after learning that a close family member, with whom he had contact, tested positive for the virus,” the statement read. “In accordance with established COVID policies, General Thompson is self-quarantining and working remotely from home.”

The US Space Force is a newly formed military service branch structured within the Department of the Air Force that “trains, equips and maintains mission-ready space forces that provide missile warning, space domain awareness, positioning, navigation and timing, communications and space electronic warfare,” according to the US Defense Department.

Thompson isn’t the first Defense Department official to have been diagnosed with the virus. The vice commandant of the US Coast Guard, Adm. Charles Ray, tested positive for Covid-19 earlier this month. His diagnosis prompted Joint Chiefs of Staff Chairman Mark Milley and several members of the Pentagon’s senior leadership to quarantine.
Additionally, during the coronavirus outbreak among members of President Donald Trump’s inner circle who had attended a Rose Garden event earlier this month, at least one staffer — who is military personnel directly assigned to support the President in the Oval Office and residence — tested positive, according to a person familiar with the matter at the time.
The Defense Department has struggled with several coronavirus outbreaks during the pandemic. CNN reported earlier this month that the coronavirus had returned to the USS Theodore Roosevelt, the same aircraft carrier that experienced a major outbreak earlier this year, the handling of which caused the ship’s captain to be fired and led to the resignation of the acting Navy secretary.
In March, the department banned travel for members of the armed services, Defense Department civilian employees and their family members who are living on or serving at military properties to curtail the spread of the coronavirus.
As of Wednesday morning, there had been 81,288 cases of coronavirus and 105 deaths from the virus among Defense Department personnel, according to department data. That includes military, civilian, dependents and contractors.

Source Article

Read More

Space Force’s No. 2 officer tests positive for Covid-19

The Space Force’s No. 2 officer has tested positive for coronavirus, the service announced Wednesday night.

Pamela Melroy et al. sitting at a table: Then-Lt. Gen. David Thompson, left, testifies before the Senate Aviation and Space Subcommittee in May 2019.

© Chip Somodevilla/Getty Images
Then-Lt. Gen. David Thompson, left, testifies before the Senate Aviation and Space Subcommittee in May 2019.

Gen. David Thompson, the vice chief of space operations, took a test after a close family member also tested positive, according to a news release. He is self-quarantining and working from home.

Despite one of the service’s top officers being sidelined with the virus, the Space Force “remains operationally ready to answer the nation’s call,” the release said.

Video: UN Chief: conflicts must stop to prevent COVID (Associated Press)

UN Chief: conflicts must stop to prevent COVID



Contact tracing to determine if other military leaders may have been exposed to Thompson was underway Wednesday night, an Air Force spokesperson said. Air Force Secretary Barbara Barrett, Chief of Space Operations Gen. John Raymond and Air Force Chief of Staff Gen. C.Q. Brown all tested negative within the last 24 hours, she said.

The news comes three weeks after the Coast Guard’s second in command, Adm. Charles Ray, tested positive, forcing members of the Joint Chiefs of Staff and other high-ranking military officials who had been in contact with Ray during a meeting at the Pentagon to self-quarantine.

Assistant Commandant of the Marine Corps Gen. Gary Thomas tested positive two days later on Oct. 7. No other members of the Joint Chiefs got sick and all were cleared to return to work after a two-week quarantine.

Continue Reading

Source Article

Read More

How much bias is too much to become a police officer? Experts fear policing law might backfire

An ambitious new law in California taking aim at potential biases of prospective officers has raised questions and concerns among police officers and experts who fear that if implemented inadequately, the law could undermine its own mission to change policing and culture of law enforcement.

a person holding a sign: A billboard in the town of Marysville, Calif., on Saturday, June 20, 2020. (Photo by Melina Mara/The Washington Post/file)

© Melina Mara/The Washington Post
A billboard in the town of Marysville, Calif., on Saturday, June 20, 2020. (Photo by Melina Mara/The Washington Post/file)

The law, which was signed by Gov. Gavin Newsom on Sept. 30, will expand the present screening requirements by mandating all law enforcement agencies to conduct mental evaluations of peace officer candidates to identify both implicit and explicit biases against race, ethnicity, gender, religion and sexual orientation in order to exclude unfit recruits.

While experts, police unions and lawmakers agree on the value of identifying whether those who aspire to become officers carry considerable degrees of biases, it is the lack of clarity on what tools and measures will be used to look for implicit biases that is raising concerns and prompting questions.

“If police departments start to reject applicants because they have implicit biases there will be no one left to hire,” said Laurie Fridell, professor of Criminology at the University of South Florida and founder of the Fair and Impartial Policing program, one of the most popular implicit bias awareness trainings in the country.

Under the new law, the state Commission on Peace Officer Standards and Training (POST) will review and develop new regulations and screening materials to identify these potential explicit and implicit biases. It will be up to each agency in the state to determine how to administrate them.

POST information officer Meagan Catafi would not say whether implicit bias tests will be part of the new screenings, arguing “it is too premature at this point to know what will be assessed and used in our materials.”

Catafi said POST will be working with psychologists and law enforcement experts to incorporate these new required items to the current psychological screening manual and have until January 2022 to complete the process.

The law comes amid a moment of social upheaval where police departments across the country are facing scrutiny and increasing calls for accountability over cases of slayings of unarmed civilians and excessive use of force that predominantly affects minorities.

This has prompted many agencies to ramp up efforts to identify racist and other discriminatory beliefs that could lead to destructive behavior, mostly by incorporating bias, diversity and inclusion training programs for active officers.

None of the experts interviewed by The Washington Post claimed to know of law enforcement agencies that screen for unconscious biases — those that people are unwilling or unable to identify — as a hiring standard. All of them, however, are either wary of such approach or advice against it.

“This is a tough one. What do you do if someone tests positive for racism?” Do you train them again? Do you fire them? There are a lot of unknowns about how this

Read More